{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:42:40Z","timestamp":1761514960329,"version":"3.37.3"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Opioids are used for acute and chronic pain in patients with sickle cell disease. How outpatient opioid regimens relate to acute care visits is of interest given the risks of high opioid doses and high hospital utilization. A prior study by our group suggested that outpatient opioid treatment for chronic pain could contribute to a vicious cycle of treatment-refractory acute pain, greater acute care utilization, and escalating opioid doses. The present larger naturalistic observational study was undertaken to determine whether the results were reliable across multiple acute care settings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One year of clinical data on patients (n\u2009=\u2009291) followed in the Sickle Cell Center for Adults (August 2018 to July 2019) were extracted, including visits to the emergency department, visits to the infusion center, and inpatient admissions. Outpatient opioid dosage was used to predict acute care treatment in generalized linear models that were controlled for patient, disease, and treatment characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Outpatient opioid dosage predicted dosage during visits but did not predict visit length or pain relief. Higher outpatient opioid dosage was associated with greater number of visits. However, in post hoc analyses, this relationship was nonlinear, with a clear positive association only for those prescribed the lowest 50% of dosages.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Higher outpatient opioid dosage predicted higher dosages during acute care visits to achieve the same pain score improvement, which is more consistent with opioid tolerance than with treatment-refractory pain. The relationship of outpatient opioid dosage with number of acute care visits was more complex, which suggests that opioid consumption at lower levels is driven by intermittent acute pain and opioid consumption at higher levels is driven by chronic pain.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/pm\/pnac187","type":"journal-article","created":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T23:10:53Z","timestamp":1669936253000},"page":"703-712","source":"Crossref","is-referenced-by-count":6,"title":["The Complex Association of Daily Opioid Dose with Visits for Pain in Sickle Cell Disease: Tolerance or Treatment-Refractory Pain?"],"prefix":"10.1093","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1726-7193","authenticated-orcid":false,"given":"Elizabeth J","family":"Prince","sequence":"first","affiliation":[{"name":"Psychiatry and Behavioral Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9752","authenticated-orcid":false,"given":"Lydia H","family":"Pecker","sequence":"additional","affiliation":[{"name":"Medicine and Obstetrics and Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2878-0251","authenticated-orcid":false,"given":"Sophie","family":"Lanzkron","sequence":"additional","affiliation":[{"name":"Medicine and Oncology, Johns Hopkins University School of Medicine , Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-916X","authenticated-orcid":false,"given":"C Patrick","family":"Carroll","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioral Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"2","key":"2023100214491217400_pnac187-B1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023100214491217400_pnac187-B2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.15169","article-title":"Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant","volume":"184","author":"Darbari","year":"2019","journal-title":"Br J Haematol"},{"issue":"4","key":"2023100214491217400_pnac187-B3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.transci.2019.04.029","article-title":"Chronic pain persists in adults with sickle cell disease despite regular red cell transfusions","volume":"58","author":"Karafin","year":"2019","journal-title":"Transfus Apher Sci"},{"issue":"12","key":"2023100214491217400_pnac187-B4","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood-2010-12-327429","article-title":"Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease","volume":"118","author":"Hillery","year":"2011","journal-title":"Blood"},{"issue":"12","key":"2023100214491217400_pnac187-B5","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.pain.2014.05.030","article-title":"Cold hypersensitivity increases with age in mice with sickle cell disease","volume":"155","author":"Zappia","year":"2014","journal-title":"Pain"},{"issue":"4","key":"2023100214491217400_pnac187-B6","doi-asserted-by":"crossref","first-page":"e765","DOI":"10.1097\/PR9.0000000000000765","article-title":"Peripheral nerve pathology in sickle cell disease mice","volume":"4","author":"Sadler","year":"2019","journal-title":"Pain Rep"},{"issue":"1","key":"2023100214491217400_pnac187-B7","first-page":"62","article-title":"Sickle cell mice exhibit mechanical allodynia and enhanced responsiveness in light touch cutaneous mechanoreceptors","volume":"8","author":"Garrison","year":"2012","journal-title":"Mol Pain"},{"issue":"8","key":"2023100214491217400_pnac187-B8","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1097\/j.pain.0000000000001253","article-title":"Chemokine (c-c motif) receptor 2 mediates mechanical and cold hypersensitivity in sickle cell disease mice","volume":"159","author":"Sadler","year":"2018","journal-title":"Pain"},{"issue":"12","key":"2023100214491217400_pnac187-B9","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: Management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2023100214491217400_pnac187-B10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pds.4291","article-title":"Characterization of opioid use in sickle cell disease","volume":"27","author":"Han","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"2023100214491217400_pnac187-B11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpain.2008.10.007","article-title":"Research gaps on use of opioids for chronic noncancer pain: Findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"issue":"4","key":"2023100214491217400_pnac187-B12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.7326\/M14-2559","article-title":"The effectiveness and risks of long-term opioid therapy for chronic pain: A systematic review for a national institutes of health pathways to prevention workshop","volume":"162","author":"Chou","year":"2015","journal-title":"Ann Intern Med"},{"key":"2023100214491217400_pnac187-B13","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCCER229","volume-title":"Opioid Treatments for Chronic Pain","author":"Chou","year":"2020"},{"issue":"2","key":"2023100214491217400_pnac187-B14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jpain.2008.10.009","article-title":"Opioids for chronic noncancer pain: Prediction and identification of aberrant drug-related behaviors: A review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline","volume":"10","author":"Chou","year":"2009","journal-title":"J Pain"},{"issue":"2","key":"2023100214491217400_pnac187-B15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/j.pain.0000000000000763","article-title":"New-onset depression following stable, slow, and rapid rate of prescription opioid dose escalation","volume":"158","author":"Salas","year":"2017","journal-title":"Pain"},{"issue":"9","key":"2023100214491217400_pnac187-B16","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jpain.2015.05.010","article-title":"Symptoms of depression are associated with opioid use regardless of pain severity and physical functioning among treatment-seeking patients with chronic pain","volume":"16","author":"Goesling","year":"2015","journal-title":"J Pain"},{"issue":"5","key":"2023100214491217400_pnac187-B17","doi-asserted-by":"crossref","first-page":"e218782","DOI":"10.1001\/jamanetworkopen.2021.8782","article-title":"Association of opioid consumption profiles after hospitalization with risk of adverse health care events","volume":"4","author":"Kurteva","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023100214491217400_pnac187-B18","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jad.2016.12.052","article-title":"A longitudinal study of depression among middle-aged and senior patients initiating chronic opioid therapy","volume":"211","author":"von Korff","year":"2017","journal-title":"J Affect Disord"},{"issue":"2","key":"2023100214491217400_pnac187-B19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/ALN.0000000000000963","article-title":"Differential opioid tolerance and opioid-induced hyperalgesia","volume":"124","author":"Hayhurst","year":"2016","journal-title":"Anesthesiology"},{"issue":"2","key":"2023100214491217400_pnac187-B20","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00000542-200002000-00029","article-title":"Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine","volume":"92","author":"Celerier","year":"2000","journal-title":"Anesthesiology"},{"issue":"1-2","key":"2023100214491217400_pnac187-B21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0304-3959(03)00294-X","article-title":"Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans","volume":"106","author":"Koppert","year":"2003","journal-title":"Pain"},{"issue":"1-2","key":"2023100214491217400_pnac187-B22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3959(03)00276-8","article-title":"Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal","volume":"106","author":"Angst","year":"2003","journal-title":"Pain"},{"issue":"6","key":"2023100214491217400_pnac187-B23","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/bloodadvances.2018024299","article-title":"Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease","volume":"3","author":"Tran","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2023100214491217400_pnac187-B24","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood-2013-04-498105","article-title":"Mast cell activation contributes to sickle cell pathobiology and pain in mice","volume":"122","author":"Vincent","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2023100214491217400_pnac187-B25","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.amepre.2016.02.012","article-title":"Chronic opioid therapy and central sensitization in sickle cell disease","volume":"51","author":"Carroll","year":"2016","journal-title":"Am J Prev Med"},{"key":"2023100214491217400_pnac187-B26","first-page":"4699","volume-title":"Blood","author":"Han","year":"2018"},{"issue":"9","key":"2023100214491217400_pnac187-B27","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/ajh.25168","article-title":"Predictors of acute care utilization and acute pain treatment outcomes in adults with sickle cell disease: The role of non-hematologic characteristics and baseline chronic opioid dose","volume":"93","author":"Carroll","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"2023100214491217400_pnac187-B28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/ajh.23961","article-title":"Impact of a dedicated infusion clinic for acute management of adults with sickle cell pain crisis","volume":"90","author":"Lanzkron","year":"2015","journal-title":"Am J Hematol"},{"key":"2023100214491217400_pnac187-B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.3375.3375","article-title":"A prospective multi-centered registry is feasible in sickle cell disease: Globin Regional Network for Data and Discovery (GRNDaD)","volume":"130","author":"Sears","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"2023100214491217400_pnac187-B30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-138895","article-title":"The Grndad registry: Contemporary natural history data and an analysis of real-world patterns of use and limitations of disease modifying therapy in adults with SCD","volume":"136","author":"Boye-Doe","year":"2020","journal-title":"Blood"},{"year":"2017","author":"Centers for Medicare and Medicaid Services","key":"2023100214491217400_pnac187-B31"},{"volume-title":"A Language and Environment for Statistical Computing","year":"2020","author":"Team R Development Core","key":"2023100214491217400_pnac187-B32"},{"issue":"13","key":"2023100214491217400_pnac187-B33","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/jama.2022.16844","article-title":"Effect of a postoperative multimodal opioid-sparing protocol vs standard opioid prescribing on postoperative opioid consumption after knee or shoulder arthroscopy: A randomized clinical trial","volume":"328","author":"Gazendam","year":"2022","journal-title":"JAMA"},{"key":"2023100214491217400_pnac187-B34","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajem.2020.10.038","article-title":"Comparative efficacy of therapeutics for traumatic musculoskeletal pain in the emergency setting: A network meta-analysis","volume":"46","author":"Yin","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"10","key":"2023100214491217400_pnac187-B35","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.jse.2022.05.029","article-title":"Opioid-sparing pain management protocol after shoulder arthroplasty results in less opioid consumption and higher satisfaction: A prospective, randomized controlled trial","volume":"31","author":"Jones","year":"2022","journal-title":"J Shoulder Elbow Surg"},{"issue":"5","key":"2023100214491217400_pnac187-B36","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/jhm.850","article-title":"Prediction of onset and course of high hospital utilization in sickle cell disease","volume":"6","author":"Carroll","year":"2011","journal-title":"J Hosp Med"},{"issue":"10","key":"2023100214491217400_pnac187-B37","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/ajh.21515","article-title":"The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization","volume":"84","author":"Carroll","year":"2009","journal-title":"Am J Hematol"},{"issue":"13","key":"2023100214491217400_pnac187-B38","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/jama.2010.378","article-title":"Acute care utilization and rehospitalizations for sickle cell disease","volume":"303","author":"Brousseau","year":"2010","journal-title":"JAMA"},{"issue":"9","key":"2023100214491217400_pnac187-B39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.14423\/SMJ.0000000000000526","article-title":"Examination of the patient and hospitalization characteristics of 30-day SCD readmissions","volume":"109","author":"Carroll","year":"2016","journal-title":"South Med J"},{"issue":"11","key":"2023100214491217400_pnac187-B40","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ajh.24498","article-title":"Patterns of opioid use in sickle cell disease","volume":"91","author":"Han","year":"2016","journal-title":"Am J Hematol"},{"issue":"6","key":"2023100214491217400_pnac187-B41","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00005792-199611000-00002","article-title":"Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive \u201cswitching\u201d agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"75","author":"Charache","year":"1996","journal-title":"Medicine"},{"issue":"20","key":"2023100214491217400_pnac187-B42","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"key":"2023100214491217400_pnac187-B43","article-title":"Chronic red cell transfusion therapy reduces hospitalization and ed admissions for acute pain in patients with sickle cell disease","author":"Karafin","year":"2014","journal-title":"Transfusion (Paris)"},{"issue":"6","key":"2023100214491217400_pnac187-B44","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mpd.2001.119593","article-title":"Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia","volume":"139","author":"Miller","year":"2001","journal-title":"J Pediatr"},{"issue":"10","key":"2023100214491217400_pnac187-B45","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1002\/pbc.25024","article-title":"Impact of individualized pain plan on the emergency management of children with sickle cell disease","volume":"61","author":"Krishnamurti","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2023100214491217400_pnac187-B46","doi-asserted-by":"crossref","first-page":"e27274","DOI":"10.1002\/pbc.27274","article-title":"A novel approach to reducing admissions for children with sickle cell disease in pain crisis through individualization and standardization in the emergency department","volume":"65","author":"Schefft","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2023100214491217400_pnac187-B47","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2018-2218","article-title":"Improving care for sickle cell pain crisis using a multidisciplinary approach","volume":"143","author":"Balsamo","year":"2019","journal-title":"Pediatrics"},{"issue":"suppl 1","key":"2023100214491217400_pnac187-B48","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood-2018-99-111435","article-title":"Assessing the safety and efficacy of converting adults with sickle cell disease from full agonist opioids to buprenorphine","volume":"132","author":"David","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2023100214491217400_pnac187-B49","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1526-4637.2011.01276.x","article-title":"Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain","volume":"12","author":"Wang","year":"2011","journal-title":"Pain Med"},{"issue":"1","key":"2023100214491217400_pnac187-B50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40122-021-00348-8","article-title":"Opioid taper is associated with improved experimental pain tolerance in patients with chronic pain: An observational study","volume":"11","author":"Compton","year":"2022","journal-title":"Pain Ther"},{"issue":"20","key":"2023100214491217400_pnac187-B51","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2009.723","article-title":"Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: A randomized controlled trial","volume":"301","author":"Kroenke","year":"2009","journal-title":"JAMA"},{"issue":"11","key":"2023100214491217400_pnac187-B52","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/ajh.26699","article-title":"Converting adults with sickle cell disease from full agonist opioids to buprenorphine: A reliable method with safety and early evidence of reduced acute care utilization","volume":"97","author":"David","year":"2022","journal-title":"Am J Hematol"},{"issue":"2","key":"2023100214491217400_pnac187-B53","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/acem.14382","article-title":"Ketamine administration for acute painful sickle cell crisis: A randomized controlled trial","volume":"29","author":"Alshahrani","year":"2022","journal-title":"Acad Emer Med"},{"issue":"2","key":"2023100214491217400_pnac187-B54","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/AJP.0b013e3181b511ab","article-title":"Use of low-dose ketamine infusion for pediatric patients with sickle cell disease\u2013related pain","volume":"26","author":"Zempsky","year":"2010","journal-title":"Clin J Pain"},{"issue":"1","key":"2023100214491217400_pnac187-B55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/15360288.2018.1468383","article-title":"Low-dose ketamine infusion for adjunct management during vaso-occlusive episodes in adults with sickle cell disease: A case series","volume":"32","author":"Palm","year":"2018","journal-title":"J Pain Palliat Care Pharmacother"}],"container-title":["Pain Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/painmedicine\/advance-article-pdf\/doi\/10.1093\/pm\/pnac187\/48438719\/pnac187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/24\/6\/703\/51824808\/pnac187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/painmedicine\/article-pdf\/24\/6\/703\/51824808\/pnac187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T14:50:02Z","timestamp":1696258202000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/painmedicine\/article\/24\/6\/703\/6865041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,2]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/pm\/pnac187","relation":{},"ISSN":["1526-2375","1526-4637"],"issn-type":[{"type":"print","value":"1526-2375"},{"type":"electronic","value":"1526-4637"}],"subject":[],"published-other":{"date-parts":[[2023,6,1]]},"published":{"date-parts":[[2022,12,2]]}}}